Navigation Links
Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Date:12/7/2010

molecule inhibitor of Bruton's tyrosine kinase (Btk) that is being developed by Pharmacyclics for the treatment of patients with B-cell lymphoma or leukemia. Btk plays a prominent role in B-cell lymphocyte maturation by mediating B-cell receptor (BCR) signal transduction. Recent studies indicate that some B-cell lymphomas have kinases that are activated downstream of the BCR and that suppression of this signaling by a Btk inhibitor can induce apoptosis in these cells. BCR signaling is also thought to promote malignant cell expansion and survival in chronic lymphocytic leukemia (CLL).

About Non-Hodgkin's Lymphoma  Non-Hodgkin's lymphoma (NHL) is a type of malignant disease that occurs within the lymphatic system and the fifth most common form of cancer. It is caused by the abnormal proliferation of white blood cells, which spreads through the lymphatic system.  NHL can occur at any age and is often marked by lymph nodes that are larger than normal, fever, and weight loss. NHL can be broadly classified into two main clinical categories: indolent lymphomas, mainly characterized as follicular lymphomas, which tend to grow relatively slowly; and aggressive lymphomas, mainly typified as diffuse large B-cell lymphomas (DLBCL), which grow much more rapidly. According to the National Cancer Institute's SEER database the incidence of NHL (all types including indolent and aggressive) is projected at nearly 66,000 in the United States for 2009 and approximately 19,500 patients are expected to die from this disease. According to the Leukemia & Lymphoma Society (LLS), there are approximately 452,723 people in the United States living with NHL (with active disease or in remission).

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopha
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Silicon Valley Bank, the bank ... today that examines the merger, acquisition and IPO ... According to the annual report based on 2013 data, ... since SVB started tracking the data in 2005. ... on solid healthcare M&A activity over the last few ...
(Date:7/30/2014)... LONDON , July 30, 2014  Lightlake ... developing addiction treatments based on its expertise in ... a funding commitment from a prominent international research ... a focus on promoting innovative research-based initiatives, including ... a nasal spray for the delivery of naloxone ...
(Date:7/30/2014)... , July 30, 2014   Epic ... company that designs and develops novel diagnostics to ... cancer, announced today the completion of a $30 ... included new investors RusnanoMedInvest (RMI) and Arcus Ventures, ... Pfizer Venture Investments, as well as undisclosed individual ...
Breaking Medicine Technology:Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3
... AuraSense Therapeutics, a biopharmaceutical company commercializing spherical ... and chemo-therapeutics for a variety of diseases, ... for cardiovascular disorders, has closed its Series ... a subsidiary of Abbott.  Other key individual ...
... 2011 /PRNewswire-Asia/ -- The Ministry of Health and ... Industry Development Institute (President Ko Kyung-hwa) launched a ... foreign patients by designating 38 tasks, including seven ... for medical injuries and granting permission for drug ...
Cached Medicine Technology:AuraSense Therapeutics Secures Series B Equity Investment 2Medical Korea's Medical Policy Improvement Project for Foreign Patients 2
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... New York (PRWEB) July 30, 2014 ... uncontrollable brain bleeding has filed a Xarelto lawsuit ( ... the blood thinner, Bernstein Liebhard LLP reports. According to ... for the District of Vermont on July 25th, the ... when he suffered an irreversible brain bleed that ultimately ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2
... just received a major grant from the National Center ... the National Institutes of Health (NIH) and lead Federal ... new grant creates a Center of Excellence for Research ... will focus on Alzheimers disease. The new Center has ...
... 2007. A report to be published in an upcoming ... for urgent attention to the politically sensitive issue of border ... in the face of a catastrophic flu pandemic . ... of a strain of avian influenza A (HN51) in Northern ...
... today,announced it received a $250,000 grant from the ... support services. The university will use the ... professions. The newly created program, named the ... help the university recruit and support,Hispanic women in ...
... for Eating Disorders Reports Eating Disorders Develop or ... Worsen Upon Returning ... Eating Disorders, http://www.remudaranch.com, the nation,s leading eating disorder treatment,center, ... A majority of eating disorders begin at ages 14 and ...
... Governor,Arnold Schwarzenegger held a press conference announcing ... state legislature aimed at producing,reforms to California,s ... Policies Institute issued the following statement:, ... solve California,s,health care crisis," said Jill Jenkins, ...
... YORK, Oct. 10 Philip K. Howard, Chair of Common,Good, ... in response to a recent study on health courts that ... "The American Association of Justice (formerly known as the Association ... a study that it commissioned on the ...
Cached Medicine News:Health News:Mount Sinai recognized as Center of Excellence for Research in Alzheimer's disease 2Health News:Report highlights inadequate pandemic planning as a threat to EU security 2Health News:Wal-Mart Foundation Provides Brenau University $250,000 Health Care scholarships Grant for Hispanic Women 2Health News:Wal-Mart Foundation Provides Brenau University $250,000 Health Care scholarships Grant for Hispanic Women 3Health News:Going Back to School Can Trigger Eating Disorders 2Health News:Going Back to School Can Trigger Eating Disorders 3Health News:Common Good Responds to a Trial Bar Study Opposing Health Courts 2
Kinetic and endpoint methods for the quantitative determination of creatinine in serum....
Intended for the quantitative determination of creatinine in serum, plasma, or urine. Reaction: Endpoint. Wavelength: 340 nm. Linearity: 10 mg/dL (880 mol/L). Two vials, dry powder reagents....
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
Medicine Products: